BioInvestors Network
Investors meet BioEntrepreneurs
BioAngels is an exclusive matchmaking concept for private investors such as business angels, wealthy individuals, family offices and conventional venture capital investors interested in life sciences & health technology investments.
Matchmaking
We introduce private investors to selected, innovative start-up projects at an early stage.
BioEntrepreneurs planning a spin-off or start-up in search of investors can apply with us to present their business idea to our BioAngels. The presenting teams will be prepared by us to submit all relevant information needed for deciding on an investment in the life sciences sector in an appropriate manner.
„On the BioAngels Pitch Day, it is easy to talk to the teams. That would be harder on large investment conferences. I also greatly appreciate the exchange with the other investors.“
Focus on health care sector
Our circle of investors is interested in participating in the following areas:
- Innovative drug development
- New diagnosis procedures
- Big data & digital health
- New drug technologies and approaches to regenerative drugs
- Innovative platform technologies and services
„The preparation by the team of BioM was very good and intensive. The criticizing feedback has helped us tailor our presentation to the demands of investors.“
More on the topic
09.01.2026
Ovo Labs announces world’s first rejuvenation of human eggs – hope for millions of aspiring parents
Ovo Labs, a pioneering biotechnology company from Oberschleißheim/Munich, has presented first-time efficacy data for its lead therapeutic EmbryoProtect 1 (EP1) at the UK’s largest fertility…
18.12.2025
BioM to Co-Host the 4th Session of Creative Destruction Lab (CDL) in Munich
BioM, together with its partner DEEP, the Institute for Deep Tech Innovation at ESMT Berlin, will co-host in Munich the 4th yearly session of Creative Destruction Lab (CDL), an…
16.12.2025
T-CURX raises 20 millions US-dollars series A to advance non-viral CAR-T cancer therapies
T-CURX announced a 20 Mio USD Series A first closing led by BiomedVC to fund pipeline of clinical-stage CAR-T programs and advance proprietary non-viral in vivo CAR-T platform.
T-CURX GmbH,…